Thera-SAbDab

TILAVONEMAB

>   Structural Summary
TherapeuticTilavonemab
TargetMAPT
Heavy ChainEVKVVESGGGLVQPGGSMKLSCVVSGFTFSNYWVNWVRQAPGKGLEWVAQIRLKSDNYATHYEESVKGRFTISRDDSKSSVYLQMNNLRAEDSGIYYCTNWEDYWGQGTTVTVSS
Light ChainDIVLTQSPDSLAVSLGERATISCRASQSVSTSRYSYIHWYQQKPGQPPKLLIKYASNLESGVPSRFGSGSGTDFTLNIHPLEPEDFATYYCHHSWEIPLTFGQGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (August '23)Phase-II
Estimated Status (August '23)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year RecommendedNone
Companies InvolvedAbbVie, C2N Diagnostics
Conditions Approvedna
Conditions ActiveAlzheimer's disease, Progressive supranuclear palsy
Conditions Discontinuedna
Notesna

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy